Jupiter Topco LLC bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 9,783,192 shares of the company's stock, valued at approximately $100,816,000. Jupiter Topco LLC owned approximately 13.68% of Immix Biopharma at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. J. Goldman & Co LP purchased a new position in shares of Immix Biopharma in the second quarter valued at approximately $2,049,000. Legal & General Group Plc purchased a new stake in Immix Biopharma during the 2nd quarter worth approximately $41,000. The Manufacturers Life Insurance Company purchased a new stake in Immix Biopharma during the 2nd quarter worth approximately $1,514,000. Compass Financial Management LLC acquired a new stake in Immix Biopharma during the 2nd quarter worth approximately $56,000. Finally, Allworth Financial LP acquired a new stake in Immix Biopharma during the 2nd quarter worth approximately $75,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
IMMX has been the subject of several research reports. Morgan Stanley dropped their price target on shares of Immix Biopharma from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Tuesday, August 11th. HC Wainwright lifted their target price on Immix Biopharma from $20.00 to $25.00 and gave the company a "buy" rating in a report on Monday, August 10th. Citigroup reiterated a "market outperform" rating on shares of Immix Biopharma in a report on Friday, August 14th. Needham & Company LLC started coverage on Immix Biopharma in a research note on Wednesday, July 22nd. They set a "buy" rating and a $21.00 target price for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Immix Biopharma in a report on Friday, July 17th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.29.
Get Our Latest Report on Immix Biopharma
Immix Biopharma Stock Down 2.8%
NASDAQ IMMX opened at $14.07 on Thursday. Immix Biopharma, Inc. has a 52 week low of $1.94 and a 52 week high of $15.10. The stock has a market capitalization of $1.01 billion, a PE ratio of -15.99 and a beta of 0.11. The firm has a 50 day moving average of $10.40 and a two-hundred day moving average of $9.46.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.01). On average, equities research analysts expect that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.
About Immix Biopharma
(
Free Report)
Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
